Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

161. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness

Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal

2011 Health Technology Assessment (HTA) Database.

162. Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery

Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do

2011 Evidence-Based Medicine

163. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

164. Proton Pump Inhibitors 2.0

Proton Pump Inhibitors 2.0 Proton Pump Inhibitors 2.0 – Clinical Correlations Search Proton Pump Inhibitors 2.0 November 26, 2010 5 min read By Mary C. Whitman, MD Faculty Peer Reviewed and are prescribed to over . Recently, new data has emerged that suggests that we should be more judicious in prescribing PPIs. In a recent development, the FDA announced that it will require new labeling of PPIs indicating that their use at high . This change was prompted, in part, , who took PPIs for at least (...) of proton pump inhibitors. World J Gastroenterol. 2010. 16(19):2323-30. Katz MH. Failing the Acid Test: Benefits of Proton Pump Inhibitors May not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures Among At-Risk Patients. Gastrolenterology 2010. March. Epub ahead of print. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy

2010 Clinical Correlations

165. Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction

Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction – Clinical Correlations Search Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction July 28, 2010 5 min read By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between (...) clopidogrel (Plavix®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over

2010 Clinical Correlations

166. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus Full Text available with Trip Pro

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflammatory drugs (NSAID)/aspirin, and statins may be associated with a low risk of esophageal neoplasia. However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (EAC) in patients with existing Barrett's esophagus (BE) is unclear.We conducted

2010 EvidenceUpdates

167. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention (Abstract)

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention Recent studies have suggested that proton pump inhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other

2010 EvidenceUpdates

168. Proton pump inhibitors and risk for recurrent Clostridium difficile infection Full Text available with Trip Pro

Proton pump inhibitors and risk for recurrent Clostridium difficile infection Proton pump inhibitors (PPIs) are widely used gastric acid suppressants, but they are often prescribed without clear indications and may increase risk of Clostridium difficile infection (CDI). We sought to determine the association between PPI use and the risk of recurrent CDI.Retrospective, cohort study using administrative databases of the New England Veterans Healthcare System from October 1, 2003, through (...) determined that the adjusted HR of recurrent CDI was greater in those exposed to PPIs during treatment (1.42; 95% confidence interval [CI], 1.11-1.82). Risks among exposed patients were highest among those older than 80 years (HR, 1.86; 95% CI, 1.15-3.01) and those receiving antibiotics not targeted to C difficile during follow-up (HR, 1.71; 95% CI, 1.11-2.64). [corrected]Proton pump inhibitor use during incident CDI treatment was associated with a 42% increased risk of recurrence. Our findings warrant

2010 EvidenceUpdates

169. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative Full Text available with Trip Pro

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]).This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's

2010 EvidenceUpdates

170. WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. (Abstract)

WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. Randomised controlled trials (RCTs) evaluating the clinical effect of proton pump inhibitors (PPIs) in peptic ulcer (PU) bleeding yield conflicting results.To evaluate the efficacy of PPIs in acute bleeding from PU using evidence from RCTs.We searched CENTRAL, The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to November 2004), EMBASE (1980 to November 2004), proceedings of major meetings to November 2004

2010 Cochrane

171. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial (Abstract)

Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial The primary aim of this study was to evaluate if the use of proton pump inhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses.Benign anastomotic strictures are associated with anastomotic leaks or conduit

2010 EvidenceUpdates Controlled trial quality: uncertain

172. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID nature publishing group the red section 2533 Writing Committee Members Neena S. Abraham, MD, FACG, Chair*; Mark A. Hlatky, MD, FACC, FAHA, Vice Chair† Elliott M. Antman, MD, FACC, FAHA‡; Deepak L. Bhatt, MD, MPH, FACC, FAHA† David J. Bjorkman (...) KW , Quigley EM, Scheiman J, Sper - ling LS, Tomaselli GF (. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533–2549; doi:10.1038/ajg.2010.445. This article has been copublished in the Journal of the American College of Cardiology and Circulation. Copies

2010 American College of Gastroenterology

173. Proton Pump Inhibitors for Acute Upper GI Bleeding

Proton Pump Inhibitors for Acute Upper GI Bleeding Proton Pump Inhibitors for Acute Upper GI Bleeding – TheNNTTheNNT Proton Pump Inhibitors (PPIs) Given for Acute Upper Gastrointestinal Bleeding Given Prior to Endoscopic Diagnosis No benefit found In Summary, for those who took the PPI: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death, needing surgery, preventing repeat bleeding None were helped (life saved, preventing surgery, prevent repeat bleeding) Harms in NNT (...) gastrointestinal bleeding is a potentially life threatening condition that can demand aggressive intervention from the emergency physicians. Although bleeding can originate in any area above the ligament of Treitz, the majority of bleeding is from a peptic ulcer , . Proton pump inhibitors (PPIs) work by reducing gastric acid secretion, neutralizing gastric pH, increasing clot formation and decreasing clot lysis . Intravenous proton pump inhibitors have traditionally been used after endoscopic hemostasis

2010 theNNT

174. High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis Full Text available with Trip Pro

High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis Wu LC, Cao YF, Huang JH, Liao C, Gao F CRD summary This generally well-conducted review concluded that the low-dose intravenous proton-pump inhibitors achieved the same efficacy as high-dose proton-pump (...) inhibitors following endoscopic haemostasis in patients with upper gastrointestinal bleeding. The authors' conclusions reflect the evidence presented, but should be interpreted with a degree of caution given the limited quality and size of most of the included trials. Authors' objectives To assess the efficacy of high-dose versus low-dose proton-pump inhibitors for the treatment of upper gastrointestinal bleeding. Searching The following databases were searched up to September 2009 without language

2010 DARE.

175. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis Full Text available with Trip Pro

The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients (...) : a meta-analysis Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB CRD summary This review found there were no differences in outcomes between treatment with proton pump inhibitors and histamine-2 receptor antagonists for critical care patients in intensive care units. The authors' cautious conclusions reflect the evidence presented, but the poor quality of the included trials and the potential for publication and language biases should be considered when interpreting the results. Authors' objectives

2010 DARE.

176. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

177. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials Full Text available with Trip Pro

High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer (...) : a systematic review and meta-analysis of randomized controlled trials Wang CH, Ma MH, Chou HC, Yen ZS, Yang CW, Fang CC, Chen SC CRD summary This generally well-conducted review concluded that high-dose proton pump inhibitors did not reduce re-bleeding, surgical intervention or mortality after endoscopic treatment in patients with a bleeding peptic ulcer, compared with non-high-dose proton pump inhibitors. This conclusion is likely to be reliable. Authors' objectives To determine whether high-dose proton

2010 DARE.

178. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

179. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

180. Clopidogrel and proton pump inhibitors: interaction?updated advice

Clopidogrel and proton pump inhibitors: interaction?updated advice Clopidogrel and proton pump inhibitors: interaction—updated advice - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Clopidogrel and proton pump inhibitors: interaction—updated advice In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either omeprazole or esomeprazole with clopidogrel should be discouraged (...) . Proton pump inhibitors (PPIs) are indicated for the treatment of oesophageal reflux disease, dyspepsia, or gastric ulcers, and are frequently co-prescribed with clopidogrel. Previous advice regarding an interaction In May 2009, the EU Committee for Medicinal products for Human Use (CHMP) concluded that concomitant use of any PPIs with clopidogrel should be avoided unless considered essential. See . The product information for clopidogrel has been recently updated on the basis of pharmacokinetic

2010 MHRA Drug Safety Update